Drug Pricing Texacort
View Price per Unit, Price History
Current Pricing Information
The most recent wholesale price for a package of 1 BOTTLE, WITH APPLICATOR in 1 CARTON / 30 mL in 1 BOTTLE, WITH APPLICATOR is $6.35780 per billable unit.Texacort is a a human prescription drug labeled by Mission Pharmacal Company and is priced per "ML" unit. The pricing information is based on the National Average Drug Acquisition Cost (NADAC) and is effective since 06-18-2025.
NADAC pricing data is based on random monthly surveys and reflects the average drug invoice price paid by retail community pharmacies to wholesalers. The data source for this pricing survey was a C/I - Chain or Independent Pharmacy.
Price per Unit
$6.35780
Effective Date Effective Date
The effective date of the NADAC Per Unit cost.
The effective date of the NADAC Per Unit cost.
06-18-2025
NDC Code
Package Description
1 BOTTLE, WITH APPLICATOR in 1 CARTON / 30 mL in 1 BOTTLE, WITH APPLICATOR
C/I - Chain or Independent Pharmacy
Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey.
Code 5: The NADAC was calculated based on package size.
Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.
Code 5: The NADAC was calculated based on package size.
Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.
Classification for Rate Setting Classification for Rate Setting
Indicates whether the NDC was considered brand (B) or generic (G) for the NADAC rate calculation process. If the NDC was considered brand (B) and approved under an Abbreviated New Drug Application (ANDA), the indicator is shown as (B-ANDA).
Indicates whether the NDC was considered brand (B) or generic (G) for the NADAC rate calculation process. If the NDC was considered brand (B) and approved under an Abbreviated New Drug Application (ANDA), the indicator is shown as (B-ANDA).
B-ANDA - Abbreviated New Drug Application
As of Date
07-02-2025
The Centers for Medicare and Medicaid Services (CMS) compile the NADAC data based on random monthly surveys on more than 60,000 pharmacies from all 50 states and the District of Columbia. NADAC pricing information is NOT the price paid by end-customers but instead the price paid by pharmacies to drug wholesalers and distributors.
Pricing History
The NADAC wholesale price of Texacort 0178-0455-01 has fluctuated from a low of $6.17305 to a high of $6.41039 per billable unit over a period of 1 year and 2 months. The historical price table below includes all the price changes based on the monthly surveys of retail and chain pharmacies taken by the Centers for Medicare and Medicaid Services (CMS).
| Effective Date | Price per Unit | Pricing Unit | Pharmacy Type Indicator | Explanation Code | Classification Rate Setting |
|---|---|---|---|---|---|
| 06-18-2025 | $6.35780 | ML | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 5: The NADAC was calculated based on package size. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
| 04-23-2025 | $6.39489 | ML | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 5: The NADAC was calculated based on package size. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
| 02-19-2025 | $6.41039 | ML | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 5: The NADAC was calculated based on package size. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
| 12-18-2024 | $6.39900 | ML | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 5: The NADAC was calculated based on package size. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
| 11-20-2024 | $6.35367 | ML | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 5: The NADAC was calculated based on package size. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
| 09-18-2024 | $6.22958 | ML | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 5: The NADAC was calculated based on package size. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
| 08-21-2024 | $6.24424 | ML | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 5: The NADAC was calculated based on package size. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
| 07-17-2024 | $6.28062 | ML | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 5: The NADAC was calculated based on package size. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
| 06-19-2024 | $6.22396 | ML | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 5: The NADAC was calculated based on package size. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
| 04-17-2024 | $6.17305 | ML | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 5: The NADAC was calculated based on package size. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
The pricing data in this page is based on the National Average Drug Acquisition Cost (NADAC). The NADAC data is compiled by CMS and updated every week. The NADAC dataset is designed to help create a national benchmark reflective of the wholesale prices paid by retails pharmacies to acquire prescription and over-the-counter drugs. The pricing information in this page reflects the reference point that healthcare programs like Medicaid may use to reimburse pharmacies. The pricing data is this page is NOT the price paid by end-customers.
NADAC Pricing Data Last Updated on: July 02, 2025
